The estimated Net Worth of Ventures, Llceshelman Fredr... is at least $41.3 millió dollars as of 26 January 2021. Ventures Fredr owns over 1,762,162 units of Liquidia Corp stock worth over $26,402,282 and over the last 5 years Ventures sold LQDA stock worth over $14,941,437.
Ventures has made over 20 trades of the Liquidia Corp stock since 2020, according to the Form 4 filled with the SEC. Most recently Ventures sold 1,762,162 units of LQDA stock worth $5,497,945 on 26 January 2021.
The largest trade Ventures's ever made was buying 1,875,000 units of Liquidia Corp stock on 2 July 2020 worth over $15,000,000. On average, Ventures trades about 329,442 units every 14 days since 2020. As of 26 January 2021 Ventures still owns at least 2,601,210 units of Liquidia Corp stock.
You can see the complete history of Ventures Fredr stock trades at the bottom of the page.
Over the last 6 years, insiders at Liquidia Corp have traded over $16,750,945 worth of Liquidia Corp stock and bought 12,456,625 units worth $100,694,400 . The most active insiders traders include Forest Baskett, Scott D Sandell és Peter J Barris. On average, Liquidia Corp executives and independent directors trade stock every 18 days with the average trade being worth of $1,467,274. The most recent stock trade was executed by Russell Schundler on 30 August 2024, trading 2,344 units of LQDA stock currently worth $23,792.
liquidia technologies is a biopharmaceutical company transforming the development of new therapies by precisely engineering drug particles. our proprietary print technology is a simple, elegant solution that solves common problems with drug delivery and efficacy. print technology is a scalable cgmp compliant process that creates particles and can apply to virtually any therapeutic area, molecule or route of administration. liquidia is bringing more efficient, controlled development capabilities to the industry while enhancing the safety and quality of products for patients. liquidia is advancing product candidates from its own pipeline. these initial product candidates, liq861 and liq865, apply the print technology to better drug delivery in inhaled and pain therapeutic areas, respectively. the print technology is also licensed with world-leading pharmaceutical companies that are developing future product candidates.
Liquidia Corp executives and other stock owners filed with the SEC include: